Project Grant R01HD115635
Award Date
7/15/24
Completion Date
4/30/29
Dollars Obligated
$2M
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $429,000 to the Regents of the University of Michigan to conduct research on the molecular regulators of the GABAergic system in human neurons derived from control and trisomy 21 (Down syndrome) human embryonic stem cells. The primary goal is to discover the underlying mechanisms that cause...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
This federal Project Grant award for $152,816.00, provided by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The research will focus on: Identifying transcriptional differences in implantation-stage trophoblasts between trisomy 21 and euploid induced pluripotent stem cell lines through RNA-sequencing. Assessing the...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 - Child Health and Human Development Extramural Research, aims to investigate the impact of chromosome 21 dosage on the placenta secretome and neurodevelopment. The $147,486 award to The Johns Hopkins University, effective September 21, 2025 through March 25, 2027, will test the hypothesis that increased dosage of genes on chromosome 21, such as APP and SOD1,...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), provides $451,000.00 to The University of Texas Southwestern Medical Center to develop tools for high-throughput screening to identify genes on human chromosome 21 that contribute to Down syndrome pathologies. The goal is to use CRISPR interference technology combined with induced pluripotent stem cells derived from individuals with...
This $3.44 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), will fund research at the University of Massachusetts Medical School to suppress aneuploidy-associated phenotypes in Down syndrome. Specifically, the researchers will identify the mechanisms by which an extra copy of chromosome 21 affects nuclear structure and function in cells, investigate how...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), is intended to support the application and evaluation of [18F]-BCPP-EF Positron Emission Tomography (PET) imaging for in vivo assessment of mitochondrial complex I (MC-I) function in individuals with Down syndrome (DS). The primary aim is to map the distribution of MC-I activity in the DS brain compared to healthy controls, with the...
This $3.386 million project grant from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research at Beth Israel Deaconess Medical Center to develop a potential treatment for Down syndrome. The grantee will assess the efficiency of using a modified CRISPR approach and single nucleotide polymorphism-based guide RNA targeting to silence one of three copies of human chromosome 21 in the Tc1 mouse model of Down syndrome. If successful, this research could...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...